Theratechnologies (NASDAQ:THTX – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.08), Zacks reports. The firm had revenue of $17,729 billion during the quarter, compared to analyst estimates of $24.30 million.
Theratechnologies Price Performance
Shares of Theratechnologies stock opened at $3.14 on Thursday. The stock’s fifty day moving average is $2.63 and its two-hundred day moving average is $2.09. The company has a market capitalization of $144.38 million, a PE ratio of -39.25 and a beta of 0.55. Theratechnologies has a 52 week low of $1.12 and a 52 week high of $3.20.
Wall Street Analysts Forecast Growth
Separately, Jones Trading lowered Theratechnologies from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 3rd.
Hedge Funds Weigh In On Theratechnologies
An institutional investor recently bought a new position in Theratechnologies stock. Acadian Asset Management LLC purchased a new position in shares of Theratechnologies Inc. (NASDAQ:THTX – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 28,400 shares of the company’s stock, valued at approximately $39,000. Acadian Asset Management LLC owned approximately 0.06% of Theratechnologies at the end of the most recent quarter.
Theratechnologies Company Profile
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Further Reading
- Five stocks we like better than Theratechnologies
- With Risk Tolerance, One Size Does Not Fit All
- AI Chip Arms Race: 3 Must-Watch Equipment Stocks
- Roth IRA Calculator: Calculate Your Potential Returns
- Will Oracle’s Cloud and AI Deals Propel It to New Highs?
- Pros And Cons Of Monthly Dividend Stocks
- Why Constellation, Cameco & NuScale Should Be on Your Radar
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
